0000899243-18-016532.txt : 20180614 0000899243-18-016532.hdr.sgml : 20180614 20180614083448 ACCESSION NUMBER: 0000899243-18-016532 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180612 FILED AS OF DATE: 20180614 DATE AS OF CHANGE: 20180614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 18898205 MAIL ADDRESS: STREET 1: C/O ACORDA THERAPEUTICS, INC. STREET 2: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 784 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 784 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-12 0 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001197032 SMITH IAN F C/O INFINITY PHARMACEUTICALS, INC. 784 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2018-06-12 4 A 0 22857 1.75 A 45845 D Stock Option (right to buy) 1.75 2018-06-12 4 A 0 20000 0.00 A 2028-06-12 Common Stock 20000 20000 D Stock Option (right to buy) 1.75 2018-06-12 4 A 0 4000 0.00 A 2028-06-12 Common Stock 4000 4000 D Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director. The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors. /s/ Ian F. Smith 2018-06-12